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Abstract  
 
Background: The methodology used for the application of repetitive transcranial 
magnetic stimulation (TMS) is such that it may induce a placebo effect. Respectively, 
adverse events (AEs) can occur when using a placebo, a phenomenon called nocebo. 
The primary aim of our meta-analysis is to establish the nocebo phenomena during 
TMS. Safety and tolerability of TMS were also studied. 
Methods: After a systematic Medline search for TMS randomized controlled trials 
(RCTs), we assessed the number of patients reporting at least one AE and the number 
of discontinuations because of AE in active and sham TMS groups. 
Results: Data was extracted from 93 RCTs. The overall pooled estimate of active TMS 
and placebo treated patients who discontinued treatment because of AEs was 2.5% 
(95% CI 1.9% - 3.2%) and 2.7% (95% CI 2.0% - 3.5%) respectively. The pooled estimate 
of active TMS and placebo treated patients experiencing at least one AE was 29.3% 
(95% CI 19.0% - 22.6%) and 13.6% (95% CI 11.6% - 15.8%) respectively, suggesting that 
the odds of experiencing an AE is 2.60 times higher (95% CI 1.75  ? 3.86) in the active 
treatment group compared to placebo (p<0.00001). The most common AE was 
headache, followed by dizziness. 
Secondary meta-analyses in depression and psychotic disorders showed that the odds 
of experiencing an AE is 3.98 times higher (95% CI 2.14  ? 7.40) and 2.93 times higher 
(95% CI 1.41  ? 6.07), respectively, in the active treatment groups compared to 
placebo. 
Conclusions: TMS is a safe and well-tolerated intervention. Nocebo phenomena do 
occur during TMS treatment, and should be acknowledged during clinical trial design 
and daily clinical practice. 
Highlights 
x TMS is a safe and well-tolerated intervention.  
x Serious adverse event during TMS are rare 
x Nocebo phenomena do occur during TMS treatment 
x Headache is the commonest adverse event during TMS. 
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INTRODUCTION 
 
Transcranial magnetic stimulation (TMS) is a neurostimulation and neuromodulation 
technique, based on the principle of electromagnetic induction of an electric field in 
the brain [1]. The therapeutic utility of repetitive TMS (rTMS) has been demonstrated 
in a variety of neurological [2] and psychiatric conditions [3] and has already been 
approved as a treatment for depression and migraines in many countries. 
The methodology used for the application of rTMS, such as the presence of auditory 
and somato-sensory perception, as well as the positioning a TMS coil on the head, can 
induce a placebo effect in some patients predominantly due to the belief that one is 
undergoing brain stimulation [4]. The placebo effect, as it is the case with other 
medical interventions, may add to the effects induced through activation of neural 
structures and may contribute to the subjective feeling of improvement in some 
instances [1]. Placebo phenomena during rTMS treatment have been evaluated in 
various neuropsychiatric disorders, including depression [5, 6] and schizophrenia [7]. 
Respectively, adverse events (AEs) can occur when using a placebo, a treatment with 
no active therapeutic effect. This phenomenon is called nocebo and is probably the 
result of negative expectations by patients that medical treatment will probably harm 
rather than heal [8, 9].  The fact that AEs are occurring in placebo-treated patients 
suggests that a part of the AEs reported in patients receiving active treatment is also 
because of nocebo [10, 11]. Nocebo is associated with lower adherence to the 
therapeutic interventions, higher rates of treatment withdrawal, as well as significant 
difficulty in assessing the efficacy and the safety profile of an intervention [12, 13].  
The aim of our study was to investigate the frequency and strength of nocebo 
phenomena in TMS randomized placebo-controlled trials. The AE and dropout rates 
of patients receiving active TMS and placebo treatment (nocebo AE and nocebo 
dropout rates) were used as a measure of TMS tolerability and severity of the nocebo 
effect, respectively.  
 6 
METHODS 
 
Standard protocol approvals and registrations 
This systematic review and meta-analysis was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14].  
Sham or placebo TMS 
/Ŷ dD^ ƐƚƵĚŝĞƐ ? ƚŚĞ ƚĞƌŵ  “ƉůĂĐĞďŽ ? ŝƐ ŽĨƚĞŶ ƌĞƉůĂĐĞĚďǇ ƚŚĞ ƚĞƌŵ  “ƐŚĂŵ ? ? &Žƌ ƚŚĞ
purposes of this paper the two terms are used interchangeably. Although there are 
different sham TMS approaches, they can be broadly divided into two groups [15].  
The more common approach involves utilising regular active TMS coils. These coils are 
angled off the head (either at 45° and 90°) such that only one edge remains in contact 
with the scalp. This reproduces a clicking sound, which is very similar to that of an 
active TMS pulse. Muscle twitching can also occur [15].  This method, therefore, 
preserves the somatosensory effects of active TMS, however, it is inherently difficult 
to determine whether there is any residual neuronal stimulation [15]. It has already 
been demonstrated that some sham TMS conditions produce substantial cortical 
stimulation, making it critical to carefully select the sham manipulation for clinical 
trials [16]. 
The second approach utilises commercially available sham TMS coils. These are coils 
that resemble regular TMS coils but markedly attenuate the magnetic field and can, 
therefore, be positioned exactly like the regular TMS coils. These purpose built sham 
coils mimic regular coils by reproducing the same clicking noises. Although this 
method ensures no cortical stimulation, the somatosensory effects of regular TMS 
coils is not replicated. These can be overcome with the use of surface electrodes for 
electrical stimulation of the skin to reduce such differences [15]. 
Literature search strategy 
A computer-based literature search was conducted on December 11th, 2017 on 
Medline. The Medical Subject Headings (MeSH) terms that had to be present in the 
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title and/or the abstract of the papers as well as the filters that were used are detailed 
in PROSPERO, where the protocol was prospectively registered (registration: 
CRD42017081824).   
Eligibility criteria 
We selected the articles that fulfilled the following criteria; (i) were studies testing 
TMS, (ii) were randomized controlled trials (RCTs), (iii) they included a purely placebo 
arm, (iv) they involved humans, (v) each treatment arm had at least 10 patients, (vi) 
withdrawals were reported in detail in each treatment arm, and (vii) they scored a 
JADAD score of higher than or equal to 3.  
The JADAD scale classifies the quality of reports and includes only five items. Each item 
has to be answered with either a yes (scoring 1 point) or a no (scoring 0 points). The 
items are as follows: (i) Was the study described as randomized?, (ii) Was the study 
described as double blind?, (iii) Was there a description of withdrawals and dropouts?, 
(iv) Was the method of randomisation described in the paper and was appropriate? 
and (v) Was the method of blinding described and was appropriate? [17]. 
Data extraction 
Data was extracted from each study in a structured coding scene using Excel and 
included information on article identification, year of publication, total number of 
subjects, disease where TMS was tested, number of placebo-treated subjects, number 
of placebo-treated subjects who dropped out because of AEs, number of female 
subjects treated with placebo, mean age of placebo-treated subjects, number of TMS-
treated subjects, number of TMS-treated subjects who dropped out because of AEs, 
number of female subjects treated with TMS, mean age of TMS-treated subjects, 
number of sessions, motor threshold percentage, frequency of stimulation, sham TMS 
approach (angled coil (45° versus 90°) or shielded coil) and country. Where reported, 
we also extracted information on number of placebo-treated subjects who 
experienced at least one AE, number of TMS-treated subjects who experienced at 
least one AE and the nature of AEs. On all occasions patients had to be on stable 
treatment regimens of any medical condition (i.e. comorbidities) before entering the 
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RCT. We calculated the nocebo AE rates or dropout rates for each group by pooling 
the percentage of placebo-treated or TMS-treated patients respectively, who had at 
least one AE or dropped out because of AE.   
Statistical analyses 
A database was developed using IBM SPSS Statistics (version 23.0 for Mac). 
Frequencies and descriptive statistics were examined for each variable. The outcomes 
of interest were the proportion of patients treated with TMS and placebo who 
experienced AEs, and the proportion of patients treated with TMS and placebo who 
dropped out of the study because of any AE.  
The meta-analysis was conducted using the RevMan programme (Review Manager, 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014) as suggested by the Cochrane Collaboration Group. 
Heterogeneity between studies was assessed using the I2 statistic. Data were analysed 
using a random effects model. 
The nocebo dropout and nocebo AE rates among patients treated with different 
characteristics of sham procedures (angled or shielded) and different coil positioning 
method (45° or 90°), were examined using the chi-square test 
Correlations between percentages and the characteristics of the treatment protocol 
ǁĞƌĞĞǆĂŵŝŶĞĚƵƐŝŶŐ^ƉĞĂƌŵĂŶ ?ƐĐŽƌƌĞůĂƚŝŽŶƐ ? 
A value of p<0.05 was considered to be statistically significant. The bonferroni 
correction was used in multiple comparisons.  
Data availability 
All extracted data can be shared following a reasonable request to the corresponding 
author. 
RESULTS 
The process of the article selection is presented in Figure 1. From the 302 articles 
retrieved, 93 placebo controlled RCTs were included in the meta-analysis (Supplement 
1). These studies were published between 1999 and 2017 and they involved 2290 
TMS-treated and 1854 placebo-treated patients.  The majority of TMS studies were 
conducted in patients whose principal diagnosis was depression (28.0% of the 
studies), followed by psychotic disorders (19.4%) that were grouped together (i.e. 
ƐĐŚŝǌŽƉŚƌĞŶŝĂ ĂŶĚ ƐĐŚŝǌŽĂĨĨĞĐƚŝǀĞ ĚŝƐŽƌĚĞƌ ? ? ƐƚƌŽŬĞ  ? ?  ? ?A? ? ? WĂƌŬŝŶƐŽŶ ?Ɛ ĚŝƐĞĂƐĞ
(7.5%) and pain (6.5%). The main characteristics of the studies and their populations 
are presented in Table 1. Detailed characteristics and breakdown of JADAD scores per 
study are provided (Supplements 2 and 3 respectively). 
Dropout rates in placebo and TMS groups 
The overall pooled estimate of the percentage of placebo treated patients who 
withdrew from treatment was 9.4% (95% CI 8.1% - 10.9%). The pooled estimate of the 
percentage of placebo treated patients who withdrew from treatment because of AEs 
was 2.7% (95% CI 2.0% - 3.5%). 
The pooled estimate of the percentage of TMS treated patients who withdrew from 
treatment was 9.1% (95% CI 7.9% - 10.3%). The pooled estimate of the percentage of 
TMS treated patients who withdrew treatment because of AEs was 2.5% (95% CI 1.9% 
- 3.2%). 
Figure 2a shows that the odds of dropping out because of an adverse event did not 
differ between the placebo and TMS treatment arms (Odds Ratio 0.91, 95% CI 0.60  ? 
1.38, p=0.66). The heterogeneity in reporting withdrawals because of AEs and 
experiencing at least one AE was minimal (I2 = 0%), which rendered pooling studies 
together appropriate. The symmetry of funnel plot (figure 2b) only suggest a small 
possibility of publication bias and a small study effect.  
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Adverse event rates in placebo and TMS groups 
Fifty-seven studies reported in detail the exact number of patients experiencing at 
least one AE in both study groups. The pooled estimate of the percentage of placebo 
treated patients with at least one AE was 13.6% (95% CI 11.6% - 15.8%), in comparison 
to 29.3% (95% CI 19.0% - 22.6%) for TMS treated patients.  
As illustrated in Figure 3a, the odds of experiencing an adverse event was 2.60 times 
higher (95% CI 1.75  ? 3.86) in the active treatment group compared to placebo 
(p<0.00001) (Figure 3a). 
Heterogeneity in reporting AEs was moderate (I2 =  49%), which rendered pooling 
studies together appropriate. The symmetry of funnel plot (figure 3b) only suggest a 
small possibility of publication bias and a small study effect.  
Nature of AE in placebo and TMS groups 
The most commonly reported AE in both groups were discomfort at the stimulation 
site / headache (10.1% (95% CI 8.4% - 12.0%) for placebo treated patient versus 19.7% 
(95% CI 17.7% - 21.9%) for active TMS treated patients. The second commonest AE in 
both groups was dizziness (1.8% (95% CI 1.1% -2.8%) for placebo treated versus 2.8% 
(95% CI 2.0% - 3.8%) for active TMS treated patients. Occurrence of seizures during 
treatment was extremely rare (0.2% in the placebo group and 0.1% in the active 
treatment group).  
As illustrated in the forest plot (Figure 4) the odds of experiencing 
discomfort/headache was 2.19 times higher (95% CI 1.52  ? 3.14) in the active 
treatment group compared to placebo (p<0.0001). The odds of experiencing dizziness 
did not differ significantly between the active TMS and the placebo arms (Odds Ratio 
1.47, 95% CI 0.82  ? 2.64, p=0.20).  
Determinants of AE in placebo and TMS groups 
Correlations between AE rate and withdrawal rate because of AE and various 
parameters including treatment protocol, study characteristics and demographics are 
summarized in Table 2. After adjusting for multiple comparisons, the only statistically 
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significant correlation observed was between age and AE rate in the group of patients 
ƚƌĞĂƚĞĚǁŝƚŚĂĐƚŝǀĞdD^ ?ƚŚĞŚŝŐŚĞƌƚŚĞĂŐĞ ?ƚŚĞƐŵĂůůĞƌƚŚĞƌĂƚĞ ?ƐƉĞĂƌŵĂŶ ?ƐƌŚŽ
-0.470, p<0.001). 
Also, as the number of patients in the active TMS group experiencing AEs increased, 
the number of patients in the placebo group also experiencing AEs increased 
 ?^ƉĞĂƌŵĂŶ ?ƐƌŚŽ ? ? ? ? ? ?ƉAM ? ? ? ? ? ? ? Similarly, the higher the number of patients in the 
active TMS groups that were withdrawing because of AE was, the higher the number 
of patients in the placebo groups that were withdrawing because of AE was 
 ?^ƉĞĂƌŵĂŶ ?ƐƌŚŽ ? ? ? ? ? ?ƉAM ? ? ? ? ? ? ? 
No differences were observed in the nocebo dropout rate between the patients who 
received placebo treatment with an angled TMS coil in comparison to the patients 
that received placebo treatment with a shielded TMS coil (2.4% versus 3.1%, p=0.332). 
However the nocebo AE rate was higher in the patients who received placebo 
treatment with an angled TMS coil in comparison to the patients that received placebo 
treatment with a shielded TMS coil (16.8% versus 10.5%, p=0.002). 
When comparing the nocebo dropout rate between the angled TMS coil at 45° in 
comparison to the angled TMS coil at 90°, no differences were observed (3.4% versus 
2.8%, p=0.699). However, the nocebo AE rate was higher in the patients who received 
placebo treatment with an angled TMS coil at 45° in comparison to the patients that 
received placebo treatment with an angled TMS coil at 90° (15.6% versus 7.1%, 
p<0.001). 
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Adverse events in placebo and TMS groups per disease 
There were a sufficient number of RCTs to allow for secondary meta-analyses in 
depression and psychotic disorders, including calculation of odds ratios.  Pooled data 
in other disease groups are summarized in Table 3. 
Depression 
The active TMS dropout rate because of AEs was 3.2% (95% CI 2.0% - 4.8%) and the 
nocebo dropout rate was 2.2% (95% CI 1.2% - 3.8%). The active TMS AE rate was 35.2% 
(95% CI 30.6% - 40.0%) and the nocebo AE rate was 12.2% (95% CI 8.9% - 16.3%). 
The chance of dropping out because of an adverse event did not differ between the 
placebo and the TMS treatment arms (Odds Ratio 1.70, 95% CI 0.78  ? 3.73, p=0.18), 
but the chance of experiencing an adverse event was 3.98 times higher (95% CI 2.14 
 ? 7.40) in the active treatment group compared to placebo (p<0.00001) 
Psychotic disorders 
The active TMS dropout rate because of AEs was 2.3% (95% CI 1.1% - 4.2%) and the 
nocebo dropout rate was 3.9% (95% CI 2.0% - 6.7%). The active TMS AE rate was 34.0% 
(95% CI 28.7% - 39.5%) and the nocebo AE rate was 16.6% (95% CI 11.7% - 22.5%). 
The chance of dropping out because of an adverse event did not differ between the 
placebo and the TMS treatment arms (Odds Ratio 0.53, 95% CI 0.21  ? 1.33, p=0.18), 
however the chance of experiencing an adverse event was 2.93 times higher (95% CI 
1.41 ? 6.07) in the active treatment group compared to placebo (p=0.004). 
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DISCUSSION 
 
Our meta-analysis included randomized placebo-controlled TMS trials in various 
neurological and psychiatric conditions. Our findings suggest that TMS is a well-
tolerated intervention as the rate of dropouts because of AEs is small and does not 
differ significantly between treatment with sham or active TMS (2.7% and 2.5% 
respectively).  
Serious AE were extremely rare and in particular the prevalence of seizures was 
extremely low, not differing between the active TMS and the placebo groups. Only 
one patient receiving active TMS had a seizure during one of the trials [18]. The patient 
suffered from depression and no cause for the seizure was identified [18]. Only two 
patients receiving sham TMS have been reported to had a seizure; one was a patient 
with alcohol dependence who discontinued the benzodiazepines for the purposes of 
the study and, therefore, the seizure was considered to be related to this [19], and 
one patient suffered from depression and no cause for the seizure was identified [20].  
We were able to perform secondary analyses looking separately into the RCTs where 
TMS or placebo were used in depression and psychotic disorders. In depression, the 
nocebo AE rate in TMS RCTs was 12.2% and the nocebo dropout rate was 2.2%. These 
figures are significantly lower compared to the respective figures of nocebo rates in 
pharmacological RCTs of depression, where the pooled estimates are 44.7% and 4.5% 
respectively [9]. This finding suggests that nocebo depends on the method of 
treatment. Nocebo phenomena in pharmacological RCTs of psychotic disorders  ? to 
our knowledge  ? have not yet been described. 
One of the major determinants of nocebo, if not the most important, is the uncertainty 
ŽĨƚƌĞĂƚŵĞŶƚĂĐƚŝŽŶ ?ǁŚŝĐŚƉĞƌǀĂĚĞƐĂůůĐůŝŶŝĐĂůƚƌŝĂůƐ ?ĂŶĚƉĂƌƚŝĐƵůĂƌůǇďƌĂŝŶĚŝƐĞĂƐĞƐ ?
trials [21]. Whether nocebo phenomena depend on the underlying disease or on the 
actual treatment remains debatable. On one hand, nocebo varies significantly among 
neurological conditions [22 - 32]. Moreover, Zaccara et al, showed that nocebo rates 
in RCTs may be affected by the clinical condition for which the experimental drug is 
given [33]. For example, placebo-treated patients in pain RCTs where anticonvulsants 
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are used have significantly higher proportions of intolerable AEs leading to drug 
withdrawal compared to placebo-treated patients in epilepsy RCTs where 
anticonvulsants are used [33]. On the other hand, the nature of nocebo AEs 
experienced might depend on the active drug [27, 34]. This has been demonstrated, 
in anti-migraine RCTs, where anorexia and memory difficulties, which are typical AEs 
of anticonvulsants, were present only in the placebo arm of anticonvulsants trials. This 
suggests that the AEs in placebo arms of clinical trials of anti-migraine medications 
might depend on the adverse events of the active medication against which the 
placebo is compared, which is in accordance with the expectation theory of placebo 
and nocebo effects [34]. In TMS RCTs, the nature of AE and the AE and dropout rates 
did not differ between diseases (where secondary meta-analyses where performed). 
Interestingly, the type of sham plays a role in the nocebo AE rates as angled coils lead 
to higher nocebo rates of AE. This possibly relates to the fact that the coil is not 
shielded, meaning that the produced magnetic field can be sufficient enough to cause 
a mild degree of brain stimulation [15]. Therefore, in TMS RCTs the use of shielded 
TMS coils producing a similar acoustic and somatosensory effect through other means 
(such as the use of surface electrodes) is better as it would avoid a residual brain 
stimulation that is likely occurring when angled active coils are used. Moreover, the 
higher the AE and dropout rates was reported in the active TMS groups, the higher 
the AE and dropout rates was reported in the placebo groups. A possible explanation 
for this observation is that different information might be given to the participants in 
different trials, highlighting the likely AEs of treatment and thereby increasing the 
likelihood of their occurrence. 
Limitations 
Our results should be interpreted with some caution given the limitations of our study 
design.  
Firstly, although our measures of nocebo were calculated from the trial drop-outs 
designated as treatment-related, and the AEs that were classified as treatment-
related, the inherent difficulty in attribution of non-specific symptoms has to be 
recognized as a potential source of bias. Secondly, nocebo severity is an indirect 
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estimation using dropout rate as a proxy measure. Thirdly, our literature search 
strategy was limited to the Medline database, which means that we may have missed 
studies that were unpublished or published only on other databases. Finally, we were 
ĂďůĞƚŽƉĞƌĨŽƌŵƐĞĐŽŶĚĂƌǇĂŶĂůǇƐĞƐŽŶůǇŝŶĚĞƉƌĞƐƐŝŽŶĂŶĚƉƐǇĐŚŽƚŝĐĚŝƐŽƌĚĞƌƐ ?ƚƌŝĂůƐ
and therefore, whether the nocebo AE and nocebo dropout rates differ amongst other 
diseases where TMS has been tried, remains to be determined. However, the overall 
AE and dropout rates does not differ when looking separately at the pooled rates in 
depression and psychotic disorders, which account for half of the studies used for the 
primary analysis.  
Conclusions 
TMS is a safe and well-tolerated intervention. Nocebo phenomena do occur during 
TMS treatment, and should be acknowledged during clinical trial design and daily 
clinical practice. 
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CAPTIONS 
Table 1. Descriptive characteristics of studies included in the analysis 
Table 2. Correlations between percentage of patients experience at least one adverse 
event (AE) or withdrawing because of AE and various parameters (TMS characteristics, 
study characteristics, demographics). After adjusting for multiple comparisons (n=14), 
level of statistical significance is set at p<0.0036). * Statistically significant correlation, 
after having adjusted for multiple comparisons. 
Table 3. Nocebo adverse event (AE) and dropout rates per disease where TMS was 
studied. 
 
Figure 1. PRISMA chart 
Figure 2a. Forest plot showing that the odds of dropping out because of an adverse 
event did not differ between the placebo and TMS treatment arms 
Figure 2b. Respective funnel plot 
Figure 3a. Forest plot showing that the odds of experiencing an adverse event is 
higher in the TMS arm. 
Figure 3b. Respective funnel plot 
Figure 4. Forest plot showing that the odds of experiencing headache/discomfort is 
higher in the TMS arm. 
 
Supplement 1. Studies included in this meta-analysis 
Supplement 2. Study characteristics per study 
Supplement 3. Breakdown of total JADAD score per study 
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